A Phase 2/3 interventional study of Linsitinib and Placebo in Thyroid Eye Disease, Graves Orbitopathy and Endocrine System Diseases, sponsored by Sling Therapeutics, Inc.. Completed at 30 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-23.
Sponsored by Sling Therapeutics, Inc. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Graves Ophthalmopathy with a site in United States — 12 open to participants now, 18 under way, 8 of them phase 3. Graves Ophthalmopathy · United States.
Among the 53 studies in Graves Ophthalmopathy with a site in United States, this one is the 19th largest by enrollment of the 47 interventional ones that give a count, is one of 5 that started in 2022, is one of 3 in phase 2/3, and was the 18th registered.
199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.
Browse Graves Ophthalmopathy studies →12 of the 53 studies in Graves Ophthalmopathy with a site in United States are open now. Recruiting first, the newest first:
Minghui Pharmaceutical (Hangzhou) Ltd · Sites in United States
Ages 18–75
Minghui Pharmaceutical (Hangzhou) Ltd · Sites in United States
Ages 18–75
Sling Therapeutics, Inc. · Sites in United States
Ages 18+
Ethyreal Bio, Inc. · Sites in United States
Ages 18+ · Healthy volunteers
Amgen · Sites in United States, Poland, Spain and 1 more country
Ages 18–99
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 14 · Phase 3 24 · Phase 4 5
First in 2006; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 90 is above the median of 63 across 146 interventional studies indexed under Graves Ophthalmopathy.
Median enrollment 84 across the 47 interventional studies, 100 across the 5 observational. Of the 33 that completed or were terminated, 17 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 53 have an industry lead sponsor. The 10 most frequent:
Sling Therapeutics, Inc. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Sling Therapeutics, Inc. has 3 studies filed under Graves Ophthalmopathy — fewer than ten, so there is no comparison to draw.
4 of the studies in Graves Ophthalmopathy with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06401044AmgenA Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease | 2027-01-06 |
| NCT07832136Viridian Therapeutics, Inc.An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to Teprotumumab | 2027-04 |
| NCT07623837THYROSCOPE INC.Clinical Validation of AI-Based Quantitative Eye Movement Analysis From Smartphone 9-Gaze Videos (Glandy EOM) | 2027-06-30 |
| NCT07623993THYROSCOPE INC.Prospective Observational Study of Smartphone-Based AI Self-Monitoring During Non-Surgical Treatment for Thyroid Eye Disease (THYROSCOPE) | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 53 studies in Graves Ophthalmopathy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twice daily (BID) vs. placebo, at 24 weeks in the treatment of subjects with active, moderate to severe thyroid eye disease (TED).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo Arm
Drug: Placebo
Active Arm Low Dose Linsitinib
Drug: Linsitinib
Active Arm High Dose Linsitinib
Drug: Linsitinib
Study medication taken twice daily by mouth
Placebo taken twice daily by mouth
Percentage of Subjects Who Are Proptosis Responders at Week 24
Proptosis response is defined as a ≥ 2 mm reduction from Baseline in the primary study eye without deterioration (≥ 2 mm increase) of proptosis in the contralateral non-study eye.
Time frame: 24 weeks
Percentage of Subjects Who Are Overall Responders at Week 24
Overall response is defined as a \>= 2-point reduction from baseline CAS and \>= 2 mm reduction in proptosis in the primary study eye at week 24 without deterioration (\>= 2-point increase) in CAS or deterioration (\>= 2 mm increase) of proptosis in the contralateral non-study eye. In the event of death, the latest CAS/proptosis observations will be carried forward. Missing values of CAS and proptosis measurement in the primary study eye and contralateral non-study eye at week 24 are multiple imputed by using all available prior CAS/proptosis measures, smoking status and treatment group.
Time frame: 24 weeks
Percentage of Subjects With a CAS Value of 0 or 1 at Week 24
A CAS value of 0 or 1 in primary study eye at week 24. In the event of death, the latest CAS observation will be carried forward. Missing values of CAS at week 24 are multiple imputed by using all available prior CAS measures, smoking status and treatment group
Time frame: 24 weeks
Change From Baseline in the Graves' Ophthalmopathy Quality of Life (GO-QoL) Questionnaire Overall Score to Week 24.
Change from baseline to week 24 in Graves' Ophthalmology Quality of Life (GO-QoL) overall score or to last assessed value in case of death. Missing values of GO-QoL overall score up to week 24 are multiple imputed by using all available prior GO-QoL overall score measures, smoking status and treatment group. Overall scale was measured from 0 minimum to 100 maximum (0 is worse health state and 100 is best health state)
Time frame: 24 weeks
Participants were recruited at investigative clinic sites and through central recruitment.
| Milestone | Placebo BID | 75 mg BID | 150 mg BID |
|---|---|---|---|
| Started | 30 | 30 | 30 |
| Completed | 22 | 23 | 22 |
| Not completed | 8 | 7 | 8 |
Proptosis response is defined as a ≥ 2 mm reduction from Baseline in the primary study eye without deterioration (≥ 2 mm increase) of proptosis in the contralateral non-study eye.
| % of participants | Placebo BID | 75 mg BID | 150 mg BID |
|---|---|---|---|
| Percentage of Subjects Who Are Proptosis Responders at Week 24 | 18.8 | 38.9 | 51.7 |
Overall response is defined as a \>= 2-point reduction from baseline CAS and \>= 2 mm reduction in proptosis in the primary study eye at week 24 without deterioration (\>= 2-point increase) in CAS or deterioration (\>= 2 mm increase) of proptosis in the contralateral non-study eye. In the event of death, the latest CAS/proptosis observations will be carried forward. Missing values of CAS and proptosis measurement in the primary study eye and contralateral non-study eye at week 24 are multiple imputed by using all available prior CAS/proptosis measures, smoking status and treatment group.
| % of participants | Placebo BID | 75 mg BID | 150 mg BID |
|---|---|---|---|
| Percentage of Subjects Who Are Overall Responders at Week 24 | 18.5 | 37.3 | 50.2 |
A CAS value of 0 or 1 in primary study eye at week 24. In the event of death, the latest CAS observation will be carried forward. Missing values of CAS at week 24 are multiple imputed by using all available prior CAS measures, smoking status and treatment group
| % of participants | Placebo BID | 75 mg BID | 150 mg BID |
|---|---|---|---|
| Percentage of Subjects With a CAS Value of 0 or 1 at Week 24 | 35.1 | 47.7 | 56.8 |
Change from baseline to week 24 in Graves' Ophthalmology Quality of Life (GO-QoL) overall score or to last assessed value in case of death. Missing values of GO-QoL overall score up to week 24 are multiple imputed by using all available prior GO-QoL overall score measures, smoking status and treatment group. Overall scale was measured from 0 minimum to 100 maximum (0 is worse health state and 100 is best health state)
| Score on Scale | Placebo BID | 75 mg BID | 150 mg BID |
|---|---|---|---|
| Change From Baseline in the Graves' Ophthalmopathy Quality of Life (GO-QoL) Questionnaire Overall Score to Week 24. | 0.488 ± 2.699 | 6.387 ± 2.633 | 11.264 ± 3.057 |
Collected over Adverse events were collected from time of signed informed consent through week 120 follow up.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/31 (0%) | 1/31 (3.2%) | 9/31 (29%) |
| 75 mg BID | 0/30 (0%) | 0/30 (0%) | 14/30 (46.7%) |
| 150 mg BID | 0/29 (0%) | 2/29 (6.9%) | 18/29 (62.1%) |
| Event | Placebo | 75 mg BID | 150 mg BID |
|---|---|---|---|
| Electrocardiogram T Wave AbnormalInvestigations | 0/31 | 0/30 | 1/29 |
| Guillain-Barre SyndromeNervous system disorders | 0/31 | 0/30 | 1/29 |
| Pericardial EffusionCardiac disorders | 1/31 | 0/30 | 0/29 |
| Pleural EffusionRespiratory, thoracic and mediastinal disorders | 1/31 | 0/30 | 0/29 |
| Event | Placebo | 75 mg BID | 150 mg BID |
|---|---|---|---|
| DiarrheaGastrointestinal disorders | 2/31 | 4/30 | 6/29 |
| NauseaGastrointestinal disorders | 1/31 | 3/30 | 6/29 |
| HeadacheNervous system disorders | 1/31 | 3/30 | 6/29 |
| FatigueGeneral disorders | 2/31 | 6/30 | 5/29 |
| ALT IncreasedInvestigations | 0/31 | 3/30 | 4/29 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 0/31 | 1/30 | 4/29 |
| Muscle SpasmsMusculoskeletal and connective tissue disorders | 1/31 | 2/30 | 3/29 |
| AST IncreasedInvestigations | 0/31 | 2/30 | 3/29 |
| AlopeciaSkin and subcutaneous tissue disorders | 0/31 | 3/30 | 0/29 |
| DizzinessNervous system disorders | 3/31 | 0/30 | 2/29 |
| Age, Continuous(Years) | Placebo BID | 75 mg BID | 150 mg BID | Total |
|---|---|---|---|---|
| Mean | 50.9 ± 12.70 | 52.8 ± 11.25 | 50.1 ± 14.29 | 51.3 ± 12.71 |
| Sex: Female, Male(Participants) | Placebo BID | 75 mg BID | 150 mg BID | Total |
|---|---|---|---|---|
| Female | 17 | 19 | 21 | 57 |
| Male | 13 | 11 | 9 | 33 |
| Race (NIH/OMB)(Participants) | Placebo BID | 75 mg BID | 150 mg BID | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 2 | 1 | 4 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 3 | 3 | 8 |
| White | 26 | 25 | 23 | 74 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All individual participant data collected during the trial, after deidentification will be made available.
Supporting information: Study protocol
Time frame: Beginning 3 months and ending 5 years following article publication.
Access criteria: Proposals should be directed to info@slingtx.com
Ran from Jul 2022 to primary completion in Oct 2024, 27 months.
Results were first posted in Aug 2026, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Linsitinib
Sling Therapeutics, Inc.